Figure 2: Effect of acute treatment with PMMA on locomotor activity in mice. (A) Total locomotor activity counts after acute administration of PMMA (5-30 mg/kg, i.p.) in mice. Each column represents the mean total locomotor activity counts with the S.E.M. of 13-14 animals at 120 min after drug treatment. (B) Effect of pretreatment with dopamine D1 receptor antagonist SCH23390, dopamine D2 receptor antagonist sulpiride, or 5-HT2 receptor antagonist ketanserin on the PMMA-induced hyperlocomotion in mice. For the antagonist study, SCH23390 (SCH, 0.03 mg/kg, s.c.), sulpiride (SUL, 50 mg/kg, s.c.) or ketanserin (KET, 0.3 mg/kg, s.c) was administered 10 min before treatment with PMMA (30 mg/kg). Each column represents the mean total locomotor activity counts with the S.E.M. of 12-14 animals at 120 min after drug treatment. (A) *P<0.05, **P<0.01 vs. saline (SAL)-treated group. (B) *P<0.05, **P<0.01 vs. vehicle (Veh)-saline (SAL)-treated group. ##P<0.01 vs. vehicle (Veh)-PMMAtreated group.